Apollo Therapeutics plans to launch a Phase 2 trial in the first half of 2027 to test whether its experimental vaccine APL-10456 can prevent disease flares in people with chronic obstructive pulmonary disease (COPD). According to a company press release, Apollo has completed enrollment and dosing in…

Choosing the right inhaler to deliver treatment for people with chronic obstructive pulmonary disease (COPD) may require considering their cognitive function, hand dexterity, and ability to breathe in forcefully, according to data from a large observational study in the U.S. Researchers found that nearly three in every 10 participants…